Showing results (621-630 of 2,755) with videos related to

Sort By:
Pageof 276
Pharmacogenomics|August 8, 2020
Further evidence for the association of GAL, GALR1 and NPY1R variants with opioid dependenceMatthew Randesi, Orna Levran, Wim van den Brink, et al.
Pharmacogenomics|June 5, 2014
Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroidsSusanne J H Vijverberg, Roger Tavendale, Maarten Leusink, et al.
Pharmacogenomics|June 5, 2014
Pharmacogenetics of second-generation antipsychoticsMark D Brennan
Pharmacogenomics|January 22, 2014
Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell linesChad C Brown, Tammy M Havener, Marisa W Medina, et al.
Pharmacogenomics|January 22, 2014
Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM studyRaffaele Palmirotta, Piero Barbanti, Giorgia Ludovici, et al.
Pharmacogenomics|January 22, 2014
Pharmacogenomic implications of population admixture: Brazil as a model caseGuilherme Suarez-Kurtz, Daniela Polessa Paula, Claudio J Struchiner
Pharmacogenomics|June 24, 2014
Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: a pilot studyJoseph S Rossi, Michael Cammarata, Jayalalitha Dharmavaram, et al.
Pharmacogenomics|June 24, 2014
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatmentJuan Jose Cerezo-Manchado, Vanessa Roldan, Mario Rosafalco, et al.
Pharmacogenomics|June 24, 2014
Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteinsAizati N A Daud, Jorieke E H Bergman, Marian K Bakker, et al.
Pharmacogenomics|February 26, 2015
Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosisNora Kupstyte, Remigijus Zaliunas, Vacis Tatarunas, et al.
Pageof 276